Pfizer Inc. said Friday a late-stage trial of a once-a-day formulation of its drug pregabalin did not significantly reduce the frequency of some types of seizures in patients with epilepsy
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment